Reimbursement Information   Neulasta FIRST STEP™ Program Provides information on eligibility for the Neulasta FIRST STEP™ program and how eligible patients may enroll for program benefits.     Reimbursement Connection® Provides reimbursement information on Amgen products.

Neulasta® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. Important Product Safety Information Neulasta® Prescribing Information | NEUPOGEN® (Filgrastim) Prescribing Information | Medical Information Connection™ | Site Map | Amgen.com 2009 Amgen. All rights reserved. This site for use in U.S. only.